Pfiz­er has run 41 tri­als over 15 years for tanezum­ab. As ad­comm nears, the FDA re­mains unim­pressed — and more than a lit­tle wor­ried

Ahead of an ad­vi­so­ry com­mit­tee meet­ing lat­er this week, the FDA on Mon­day re­leased its in-depth re­view of Pfiz­er and Eli Lil­ly’s an­ti-NGF os­teoarthri­tis drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.